ETF Movers on Wednesday: SIL, PBW
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2025
0mins
Should l Buy EOSE?
Source: NASDAQ.COM
- ETF Performance: The Invesco WilderHill Clean Energy ETF is down approximately 3.1% in Wednesday afternoon trading, underperforming other ETFs.
- Weakest Components: Notable declines among its components include Hyliion Holdings, which fell by about 14.9%, and Eos Energy Enterprises, which dropped by about 11.4%.
- Market Context: The article provides insights into the performance of specific ETFs and their components, reflecting broader market trends.
- Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EOSE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EOSE
Wall Street analysts forecast EOSE stock price to rise
6 Analyst Rating
2 Buy
4 Hold
0 Sell
Moderate Buy
Current: 7.110
Low
12.00
Averages
16.00
High
22.00
Current: 7.110
Low
12.00
Averages
16.00
High
22.00
About EOSE
Eos Energy Enterprises, Inc. designs, develops, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial and industrial applications. The Company has developed a range of intellectual property with multiple patents covering battery chemistry, mechanical product design, energy block configuration and a software operating system (Battery Management System or BMS). The BMS software uses proprietary Eos-developed algorithms and includes ambient and battery temperature sensors, as well as voltage and electric current sensors for the electrical strings and the system. It focuses on manufacturing and selling direct current (DC) battery energy storage systems. It also plans to develop an alternating current (AC) system. The Company offers an advanced Znyth technology battery energy storage system (BESS) designed to provide the operating flexibility to manage increased grid complexity. Its primary market is North America.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eos Energy Faces Class Action for Securities Fraud After 39% Stock Drop
- Lawsuit Background: Eos Energy Enterprises, Inc. is facing a class action lawsuit for securities fraud, involving allegations against senior executives for misleading statements regarding revenue growth and manufacturing plans, which led to a 39% stock drop on February 26, 2026.
- Stock Price Decline Reasons: Eos reported a substantial net loss of approximately $970 million for fiscal year 2025, with actual revenue falling short of the $150 million to $160 million guidance due to production inefficiencies and high expenditures impacting performance.
- Legal Action Details: Investors have until May 5, 2026, to apply to lead the case, which is pending in the U.S. District Court for the District of New Jersey, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
- Law Firm Background: Bleichmar Fonti & Auld LLP is a leading securities litigation firm that has successfully recovered over $900 million for clients, showcasing its strong capabilities in the securities class action arena.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: Boston Scientific faces a class action lawsuit for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, with investors able to file as lead plaintiffs by May 4, 2026, potentially leading to stock price pressure and diminished market confidence.
- Eos Energy Issues: Eos Energy is accused in a class action of failing to ramp up production capacity and experiencing excessive battery line downtime, with a lead plaintiff deadline of May 5, 2026, which could impact future financing and market performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is being sued for concealing safety concerns in its DCCR clinical trial, with investors able to apply as lead plaintiffs by May 5, 2026, and a successful lawsuit could result in significant compensation liabilities and reputational damage for the company.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is facing a lawsuit for not adhering to standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, and if the lawsuit is successful, it could severely impact the company's future R&D and market outlook.
See More
Eos Energy Faces Class Action Lawsuit Following 39% Share Price Drop
- Stock Price Plunge: Eos Energy's shares plummeted 39% on February 26, 2026, erasing approximately $1.4 billion in market capitalization, indicating severe investor disappointment regarding the company's financial transparency and growth prospects.
- Lawsuit Context: A securities class action lawsuit has been filed against Eos, representing investors who purchased securities between November 5, 2025, and February 26, 2026, alleging the company failed to disclose critical issues like production line downtime, resulting in significant investor losses.
- Financial Performance Failure: Eos reported a 25% revenue shortfall for FY 2025, admitting that production line downtime exceeded industry norms, which hindered its ability to meet promised production scales, further intensifying market skepticism towards its management.
- Investigation Launched: Hagens Berman is investigating whether Eos intentionally concealed manufacturing issues, urging investors and witnesses to provide information to support the inquiry into potential violations of federal securities laws.
See More
Eos Energy Faces Class Action Lawsuit
- Lawsuit Timeline: The class action lawsuit against Eos Energy targets securities purchasers from November 5, 2025, to February 26, 2026, with a deadline of May 5, 2026, for investors to seek lead plaintiff status, indicating the urgency and potential impact of the litigation.
- Financial Misstatement Allegations: The lawsuit alleges that Eos Energy failed to meet its revenue guidance of $150 to $160 million for 2025, reporting only $114.2 million, which led to a 39% drop in stock price following the announcement, reflecting significant damage to the company's market credibility.
- Production Capacity Issues: Eos Energy is accused of not achieving the required production ramp-up and experiencing downtime well above industry norms, highlighting serious deficiencies in operational efficiency and quality control within the company.
- Legal Representation Selection: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Eos Energy securities during the class period can seek lead plaintiff status, emphasizing the importance of investor participation in the legal process and its implications for potential future recoveries.
See More
Multiple Companies Face Class Action Lawsuits
- Eos Energy Lawsuit: Eos Energy Enterprises is facing allegations for failing to meet production and capacity utilization targets from November 2025 to February 2026, which could severely undermine investor confidence and negatively impact its stock performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is accused of concealing safety concerns in its DCCR clinical trials, potentially exposing patients to greater risks, which may adversely affect product acceptance and commercial viability, leading to potential investor losses.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is under scrutiny for not adhering to applicable standards in its REZOLVE-AA trial, which could compromise the integrity of trial results and affect future R&D and market strategies, creating uncertainty for shareholders.
- Driven Brands Financial Errors: Driven Brands is accused of financial reporting errors from 2023 to 2026, resulting in misstatements of cash flows and revenues, which could negatively impact its financial health and investor confidence.
See More
Eos Energy Partners with TURBINE-X for AI Power Infrastructure
- Stock Surge: Eos Energy Enterprises (EOSE) saw a 12.03% increase in stock price, closing at $7.08, primarily driven by a joint development agreement with TURBINE-X aimed at developing and deploying private power infrastructure for AI.
- Volume Spike: Trading volume reached 54 million shares, which is 116% above the three-month average, indicating strong market interest in Eos Energy's growth potential, particularly as demand for long-duration storage from data centers continues to rise.
- Significant Partnership: Eos Energy will supply TURBINE-X with 2 GWh of energy systems over the next three years, with initial deployments starting in 2027, representing a major strategic move as this amount equals Eos Energy's total production capacity in 2025.
- Future Production Plans: As Eos prepares its second production line, the company aims to support over 100 GWh deployments across multiple sites, aligning with the growing market demand for the “bring your own energy” category amid the ongoing rise of AI.
See More
Eos Energy Faces Class Action for Securities Fraud After 39% Stock Drop
- Lawsuit Background: Eos Energy Enterprises, Inc. is facing a class action lawsuit for securities fraud, involving allegations against senior executives for misleading statements regarding revenue growth and manufacturing plans, which led to a 39% stock drop on February 26, 2026.
- Stock Price Decline Reasons: Eos reported a substantial net loss of approximately $970 million for fiscal year 2025, with actual revenue falling short of the $150 million to $160 million guidance due to production inefficiencies and high expenditures impacting performance.
- Legal Action Details: Investors have until May 5, 2026, to apply to lead the case, which is pending in the U.S. District Court for the District of New Jersey, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
- Law Firm Background: Bleichmar Fonti & Auld LLP is a leading securities litigation firm that has successfully recovered over $900 million for clients, showcasing its strong capabilities in the securities class action arena.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: Boston Scientific faces a class action lawsuit for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, with investors able to file as lead plaintiffs by May 4, 2026, potentially leading to stock price pressure and diminished market confidence.
- Eos Energy Issues: Eos Energy is accused in a class action of failing to ramp up production capacity and experiencing excessive battery line downtime, with a lead plaintiff deadline of May 5, 2026, which could impact future financing and market performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is being sued for concealing safety concerns in its DCCR clinical trial, with investors able to apply as lead plaintiffs by May 5, 2026, and a successful lawsuit could result in significant compensation liabilities and reputational damage for the company.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is facing a lawsuit for not adhering to standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, and if the lawsuit is successful, it could severely impact the company's future R&D and market outlook.
See More
Eos Energy Faces Class Action Lawsuit Following 39% Share Price Drop
- Stock Price Plunge: Eos Energy's shares plummeted 39% on February 26, 2026, erasing approximately $1.4 billion in market capitalization, indicating severe investor disappointment regarding the company's financial transparency and growth prospects.
- Lawsuit Context: A securities class action lawsuit has been filed against Eos, representing investors who purchased securities between November 5, 2025, and February 26, 2026, alleging the company failed to disclose critical issues like production line downtime, resulting in significant investor losses.
- Financial Performance Failure: Eos reported a 25% revenue shortfall for FY 2025, admitting that production line downtime exceeded industry norms, which hindered its ability to meet promised production scales, further intensifying market skepticism towards its management.
- Investigation Launched: Hagens Berman is investigating whether Eos intentionally concealed manufacturing issues, urging investors and witnesses to provide information to support the inquiry into potential violations of federal securities laws.
See More
Eos Energy Faces Class Action Lawsuit
- Lawsuit Timeline: The class action lawsuit against Eos Energy targets securities purchasers from November 5, 2025, to February 26, 2026, with a deadline of May 5, 2026, for investors to seek lead plaintiff status, indicating the urgency and potential impact of the litigation.
- Financial Misstatement Allegations: The lawsuit alleges that Eos Energy failed to meet its revenue guidance of $150 to $160 million for 2025, reporting only $114.2 million, which led to a 39% drop in stock price following the announcement, reflecting significant damage to the company's market credibility.
- Production Capacity Issues: Eos Energy is accused of not achieving the required production ramp-up and experiencing downtime well above industry norms, highlighting serious deficiencies in operational efficiency and quality control within the company.
- Legal Representation Selection: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Eos Energy securities during the class period can seek lead plaintiff status, emphasizing the importance of investor participation in the legal process and its implications for potential future recoveries.
See More
Multiple Companies Face Class Action Lawsuits
- Eos Energy Lawsuit: Eos Energy Enterprises is facing allegations for failing to meet production and capacity utilization targets from November 2025 to February 2026, which could severely undermine investor confidence and negatively impact its stock performance.
- Soleno Therapeutics Risks: Soleno Therapeutics is accused of concealing safety concerns in its DCCR clinical trials, potentially exposing patients to greater risks, which may adversely affect product acceptance and commercial viability, leading to potential investor losses.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics is under scrutiny for not adhering to applicable standards in its REZOLVE-AA trial, which could compromise the integrity of trial results and affect future R&D and market strategies, creating uncertainty for shareholders.
- Driven Brands Financial Errors: Driven Brands is accused of financial reporting errors from 2023 to 2026, resulting in misstatements of cash flows and revenues, which could negatively impact its financial health and investor confidence.
See More
Eos Energy Partners with TURBINE-X for AI Power Infrastructure
- Stock Surge: Eos Energy Enterprises (EOSE) saw a 12.03% increase in stock price, closing at $7.08, primarily driven by a joint development agreement with TURBINE-X aimed at developing and deploying private power infrastructure for AI.
- Volume Spike: Trading volume reached 54 million shares, which is 116% above the three-month average, indicating strong market interest in Eos Energy's growth potential, particularly as demand for long-duration storage from data centers continues to rise.
- Significant Partnership: Eos Energy will supply TURBINE-X with 2 GWh of energy systems over the next three years, with initial deployments starting in 2027, representing a major strategic move as this amount equals Eos Energy's total production capacity in 2025.
- Future Production Plans: As Eos prepares its second production line, the company aims to support over 100 GWh deployments across multiple sites, aligning with the growing market demand for the “bring your own energy” category amid the ongoing rise of AI.
See More
